Moderna on RSV vaccine candidate: "We know it's very safe, and now we see it's effective, too"
The US-based pharmaceutical company is set to submit its RSV vaccine candidate for older adults for approval in both the US and Europe in spring.
by christian bundgaard, translated by daniel pedersen
Moderna recently presented strong data from phase III study ConquerRSV of a vaccine candidate against respiratory syncytial virus, RSV. The company’s candidate prevented 83.7% of lower respiratory tract disease from RSV, when there are more than two symptoms, in older adults.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst: New Moderna RSV data bodes well for Bavarian Nordic
For subscribers
